Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2021 09:58 ET | Source: Protagenic Therapeutics, Inc.

Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
August 30, 2021 09:15 ET | Source: Protagenic Therapeutics, Inc.

Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic...
August 17, 2021 07:45 ET | Source: Protagenic Therapeutics, Inc.

Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
July 23, 2021 16:21 ET | Source: Protagenic Therapeutics, Inc.

Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial

NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
July 06, 2021 06:17 ET | Source: Protagenic Therapeutics, Inc.

Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
April 26, 2021 20:58 ET | Source: Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering

New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a...
December 16, 2020 09:15 ET | Source: Protagenic Therapeutics, Inc.

Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial

Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava,...
June 11, 2018 10:15 ET | Source: Protagenic Therapeutics, Inc.

Three High Profile Publications Support the Potential of Protagenic Therapeutics’s Synthetic TCAP to Treat Stress-Related Psychological Disorders

Ancient, central role of brain peptide TCAP in maintenance of brain health elucidated in publications in Cell, Nature Communications, and the Journal of Neuro-endocrinology NEW YORK,...